New melanoma trial initiated at Moffitt Cancer Center to investigate utility of immunotherapy biomarkers

Phase I melanoma patient trial will test whether the drug PV-10 works better in patients with a distinct immune biomarker signature in both blood and tumor tissue.

Leave a Reply

You must be logged in to post a comment.